Lipella Pharmaceuticals Unveils New Registry for Oral Lichen Planus Research

Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has announced the launch of an Oral Lichen Planus (OLP) Patient Registry. This new online platform is designed to boost research and foster the development of treatments for OLP, a chronic inflammatory condition impacting the mucous membranes in the mouth. Symptoms of OLP include burning pain, white patches, swollen tissue, and open sores, affecting about 6 million Americans. Currently, no FDA-approved therapies exist for this condition.

The registry is now live and offers additional information on the investigational study of LP-310, an oral rinse derived from Lipella's lead candidate, LP-10, which is also being tested for hemorrhagic cystitis. Notably, LP-310 has received FDA approval for clinical evaluation in treating OLP.

Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, expressed his satisfaction with the introduction of the registry, emphasizing its role in raising awareness and accelerating research for Oral Lichen Planus. He pointed out the urgent need for effective treatment options for the millions of people affected by this condition worldwide.

Dr. Jonathan Kaufman, CEO of Lipella Pharmaceuticals, highlighted the strong interest from stakeholders in improving patient outcomes and advancing research for the OLP community. He noted that the registry aligns with the company's mission to enhance treatment approaches for this challenging condition.

For those interested in more details about the LP-310 clinical trial, they can visit the websites provided. The trial is part of a broader initiative by Lipella Pharmaceuticals to address the lack of effective treatments for debilitating conditions like OLP.

Oral Lichen Planus is a significant health issue characterized by chronic lesions in the oral mucosa, presenting substantial challenges in management. The current treatment landscape is limited, underscoring the necessity for innovative solutions. Lipella Pharmaceuticals is tackling this gap through its Phase 2a clinical trial of LP-310, a novel liposomal-tacrolimus oral rinse based on their lead candidate, LP-10, which is also being studied for hemorrhagic cystitis.

The Oral Lichen Planus Patient Registry is now accessible online, offering a valuable resource for those affected by the condition. Additional information can be found on the American Academy of Oral Medicine’s dedicated page.

Lipella Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. The company targets diseases with significant, unaddressed morbidity and mortality where no approved drug therapies currently exist. Lipella completed its initial public offering in December 2022.

By launching this patient registry, Lipella Pharmaceuticals aims to fill a critical gap in the treatment landscape for Oral Lichen Planus. This initiative is expected to drive research and potential development of new therapies, offering hope for millions of sufferers.